A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.
During dose escalation, subjects with advanced solid tumors (except for primary CNS metastases) that have progressed following at least one standard regimen
During cohort expansion, subjects with various solid tumors that have received at least one and no more than 5 prior treatment regimens
Subjects must have measurable disease
Subject must consent to provide previously collected tumor tissue
Women and men ≥18 years of age with performance status of 0 or 1
At least 4 weeks since any previous treatment for cancer
You may not be if
Active or chronic autoimmune diseases
Uncontrolled or significant cardiovascular disease
Chronic hepatitis (except for subjects with hepatocellular carcinoma)
Active infection
Active Central nervous system (CNS) metastases
Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome((HIV/AIDS)
Positive test for Hepatitis B virus surface antigen or Hepatitis C antibody (except for subjects with hepatocellular carcinoma)
Clareo Health | A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors
